ArticleBlood advances2026
The zebrafish model tackles anti-P2Y12 variability in humans: a translational approach.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAntiplatelet drugs are a pillar in the treatment strategy to prevent ischemic events in patients with cardiovascular disease. However, the action of existing therapies is nonuniform, and the causative mechanism for this variability remains poorly understood. The differences in the microRNA (miRNA) profiles among individuals have been suggested to impact platelet reactivity and treatment outcomes. In several previous clinical reports, miR-150 has been associated with platelet function variability and cardiovascular events. Therefore, we initiated our analysis by examining the mechanistic role of miR-150 in platelet function. We employed transgenic zebrafish larvae that were designed to specifically increase miR-150 expression in thrombocytes. Laser-induced caudal vein injury in these animals led to the formation of a smaller thrombus and decreased thrombocyte accumulation. RNA sequencing of miR-150-overexpressing thrombocytes identified a downregulated transcript that encoded microtubule-associated serine/threonine kinase-like (mastl), a key regulator of P2Y12 receptor downstream signaling. Overnight treatment of the transgenic fish with clopidogrel, a P2Y12 inhibitor, showed decreased thrombus formation in the control but not in the miR-150-overexpressing animals. This phenotype was reversed by overexpressing mastl. Next, we used a Vasodilator-Stimulated Phosphoprotein (VASP) phosphorylation assay to show that MASTL deficiency partially protects human platelets from P2Y12 inhibition. Finally, using miRNA:mRNA interaction predictors and experimental assays, we identified MASTL-targeting miRNAs in humans, specifically miR-17-5p and miR-106a-5p, which were significantly upregulated in a population of patients who were clopidogrel resistant. Our studies therefore support a model in which miR-150 in zebrafish and miR-17-5p or miR-106a-5p in humans modulate MASTL expression, which, in turn, alters VASP phosphorylation and platelet sensitivity to P2Y12 inhibition.
Indexed as
Identifiers
42478705What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.